FLGT vs NDAQ · rev $156.5M vs P/E 41, rev $2.53B
Fulgent Genetics Inc (FLGT) versus Nasdaq Inc (NDAQ) — a side-by-side from cached financials, not a winner call.
Fulgent Genetics Inc (FLGT) is a diagnostics & research company listed on US.
Nasdaq Inc (NDAQ) is a financial data & stock exchanges company listed on US.
Latest reported FLGT revenue for 2026-06-30 was $156.5M. Net income was -$54.4M. FLGT currently screens at market cap $586.6M.
Latest reported NDAQ revenue for 2026-06-30 was $2.53B. Net income was $507.0M. Revenue was up 18.5% from 2026-03-31 to 2026-06-30. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
FLGT currently screens at market cap $586.6M. NDAQ currently screens at market cap $51.71B and trailing P/E 40.8.
Not investment advice. Open the FLGT and NDAQ stock pages for the full models.
Not investment advice.